Eurosurv. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2

[tetano]

• Marine Maurel[SUP]1,*[/SUP] , Jennifer Howard[SUP]1,*[/SUP] , Esther Kissling[SUP]1[/SUP] , Francisco Pozo[SUP]2,3[/SUP] , Gloria Pérez-Gimeno[SUP]3,4[/SUP] , Silke Buda[SUP]5[/SUP] , Noémie Sève[SUP]6[/SUP] , Adele McKenna[SUP]7[/SUP] , Adam Meijer[SUP]8[/SUP] , Ana Paula Rodrigues[SUP]9[/SUP] , Iván Martínez-Baz[SUP]10[/SUP] , Ivan Mlinarić[SUP]11[/SUP] , Neus Latorre-Margalef[SUP]12[/SUP] , Gergő Túri[SUP]13[/SUP] , Mihaela Lazăr[SUP]14[/SUP] , Clara Mazagatos[SUP]3,4[/SUP] , Aitziber Echeverria[SUP]10[/SUP] , Stephen Abela[SUP]15[/SUP] , Marc Bourgeois[SUP]16[/SUP] , Ausenda Machado[SUP]9[/SUP] , Ralf Dürrwald[SUP]17[/SUP] , Goranka Petrović[SUP]11[/SUP] , Beatrix Oroszi[SUP]13[/SUP] , Ligita Jancoriene[SUP]18[/SUP] , Alexandru Marin[SUP]19[/SUP] , Petr Husa[SUP]20[/SUP] , Roisin Duffy[SUP]7[/SUP] , Frederika Dijkstra[SUP]8[/SUP] , Virtudes Gallardo García[SUP]21[/SUP] , Luise Goerlitz[SUP]5[/SUP] , Vincent Enouf[SUP]22[/SUP] , Charlene Bennett[SUP]23[/SUP] , Mariëtte Hooiveld[SUP]24[/SUP] , Raquel Guiomar[SUP]25[/SUP] , Camino Trobajo-Sanmartín[SUP]10[/SUP] , Vesna Višekruna Vučina[SUP]11[/SUP] , Tove Samuelsson Hagey[SUP]12[/SUP] , Ana Sofía Lameiras Azevedo[SUP]26[/SUP] , Jesús Castilla[SUP]10[/SUP] , Gerd Xuereb[SUP]15,27[/SUP] , Bénédicte Delaere[SUP]16[/SUP] , Verónica Gómez[SUP]9[/SUP] , Kristin Tolksdorf[SUP]5[/SUP] , Sabrina Bacci[SUP]28[/SUP] , Nathalie Nicolay[SUP]28[/SUP] , Marlena Kaczmarek[SUP]28[/SUP] , Angela MC Rose[SUP]1[/SUP] , on behalf of the European IVE group[SUP]29[/SUP]

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089#html_fulltext